Immuron Limited (AU:IMC) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, showcasing the company’s innovative biopharmaceutical advancements. Immuron specializes in developing oral antibodies for infectious diseases, with products like Travelan® aimed at preventing travelers’ diarrhea. The company is also working on IMM-529, a promising therapy for Clostridioides difficile infections.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
